Hindawi Publishing Corporation
Supplementary materialSUPPLEMENTARY TABLE 1 Inclusion and exclusion criteriaInclusion criteriaExclusion criteriaPopulation (P)Adult patients with CAD and PADaPatients, children, adolescents without CAD or PADInterventions (I)No intervention specifiedNot applicableComparators (C)No comparators specifiedNot applicableOutcomes (O)Epidemiology (incidence and prevalence)Disease and complication risk factorsTreatment pattern (clinical guidelines)Humanistic burden (QoL patient satisfaction, mortality, and morbidity)Economic burden (resource use including hospitalizations, cost, and absenteeism)Other outcomesStudy design (S)Observational studiesReviewsOther studiesaThe geographic scope of the review included Canada, France, Germany, Sweden, the UK and the USACAD, coronary artery disease; PAD, peripheral artery disease; QoL, quality of lifeSUPPLEMENTARY TABLE 2 Guideline recommendations on the use of antiplatelet therapy in patients with stable angina/stable CADGuideline/Country Population Recommendations ESC (2013)PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Nb250YWxlc2NvdDwvQXV0aG9yPjxZZWFyPjIwMTM8L1ll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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Nb250YWxlc2NvdDwvQXV0aG9yPjxZZWFyPjIwMTM8L1ll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ADDIN EN.CITE.DATA 1EUPatients with stable CAD Long-term low-dose aspirin (75–150 mg per day), or clopidogrel in case of aspirin intolerance, in all patients with established CAD DAPT is not routinely recommended DAPT is indicated after BMS implantation for at least 1 month DAPT is indicated for 6–12 months after implantation of second-generation DES HAS, (2016a) ADDIN EN.CITE <EndNote><Cite><Author>Haute Autorité de Santé</Author><Year>2007</Year><RecNum>14494</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>14494</rec-number><foreign-keys><key app="EN" db-id="vd5dferx1rvpw9ee2pcp5xfcazderd9xdst2" timestamp="1534248775">14494</key></foreign-keys><ref-type name="Electronic Report/Report">43</ref-type><contributors><authors><author>Haute Autorité de Santé, .</author></authors></contributors><titles><title>Artériopathie oblitérante des membres inférieurs [Obliterative arteriopathy of the lower limbs]</title></titles><dates><year>2007</year></dates><urls><related-urls><url><style face="underline" font="default" size="100%"> January 2019</access-date></record></Cite></EndNote>2 FrancePatients with stable CAD Long-term low-dose aspirin (75–160 mg per day) as monotherapy, or: Aspirin (75–160 mg per day) + clopidogrel (75 mg per day) post MI for 1 year Aspirin (75–160 mg per day) + prasugrel (100 mg per day) post MI for 1 year Aspirin (75–160 mg per day) + ticagrelor (180 mg per day) post MI for 1 year NICE, (2011 updated in 2016) ADDIN EN.CITE <EndNote><Cite><Author>National Institutes of Health</Author><Year>2011</Year><RecNum>14491</RecNum><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>14491</rec-number><foreign-keys><key app="EN" db-id="vd5dferx1rvpw9ee2pcp5xfcazderd9xdst2" timestamp="1534248775">14491</key></foreign-keys><ref-type name="Electronic Report/Report">43</ref-type><contributors><authors><author>National Institutes of Health, .</author></authors></contributors><titles><title>Stable angina: management</title></titles><dates><year>2011</year></dates><urls><related-urls><url><style face="underline" font="default" size="100%"> January 2019</access-date></record></Cite></EndNote>3UKPatients with stable angina Long-term low-dose aspirin (75 per day) SIGN (2007)a, ADDIN EN.CITE <EndNote><Cite><Author>Scottish Intercollegiate Guidelines Network</Author><Year>2007</Year><RecNum>14492</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>14492</rec-number><foreign-keys><key app="EN" db-id="vd5dferx1rvpw9ee2pcp5xfcazderd9xdst2" timestamp="1534248775">14492</key></foreign-keys><ref-type name="Electronic Report/Report">43</ref-type><contributors><authors><author>Scottish Intercollegiate Guidelines Network, .</author></authors></contributors><titles><title>Management of stable angina: a national clinical guideline 96</title></titles><dates><year>2007</year></dates><urls><related-urls><url><style face="underline" font="default" size="100%"> January 2019</access-date></record></Cite></EndNote>4ScotlandPatients with stable angina Long-term aspirin (75–150 mg per day) ACCF/AHA/ACP/AATS/PCNA/SCAI/STS (2012)PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GaWhuPC9BdXRob3I+PFllYXI+MjAxMjwvWWVhcj48UmVj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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GaWhuPC9BdXRob3I+PFllYXI+MjAxMjwvWWVhcj48UmVj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=
ADDIN EN.CITE.DATA 5USAPatients with stable ischemic heart disease Aspirin (75–162 mg per day) continued indefinitely in the absence of contraindications, or clopidogrel when aspirin is contraindicatedTreatment with aspirin (75–162 mg per day) and clopidogrel (75 mg per daily) might be reasonable in certain high-risk patientsACC/AHA (2016)PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZXZpbmU8L0F1dGhvcj48WWVhcj4yMDE2PC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZXZpbmU8L0F1dGhvcj48WWVhcj4yMDE2PC9ZZWFyPjxS
ZWNOdW0+MTMyMTU8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0
Ij42PC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MTMyMTU8L3JlYy1u
dW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ2ZDVkZmVyeDFydnB3OWVl
MnBjcDV4ZmNhemRlcmQ5eGRzdDIiIHRpbWVzdGFtcD0iMTUyMTIxMjY2OSI+MTMyMTU8L2tleT48
L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5
cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkxldmluZSwgRy4gTi48L2F1dGhvcj48
YXV0aG9yPkJhdGVzLCBFLiBSLjwvYXV0aG9yPjxhdXRob3I+Qml0dGwsIEouIEEuPC9hdXRob3I+
PGF1dGhvcj5CcmluZGlzLCBSLiBHLjwvYXV0aG9yPjxhdXRob3I+RmlobiwgUy4gRC48L2F1dGhv
cj48YXV0aG9yPkZsZWlzaGVyLCBMLiBBLjwvYXV0aG9yPjxhdXRob3I+R3JhbmdlciwgQy4gQi48
L2F1dGhvcj48YXV0aG9yPkxhbmdlLCBSLiBBLjwvYXV0aG9yPjxhdXRob3I+TWFjaywgTS4gSi48
L2F1dGhvcj48YXV0aG9yPk1hdXJpLCBMLjwvYXV0aG9yPjxhdXRob3I+TWVocmFuLCBSLjwvYXV0
aG9yPjxhdXRob3I+TXVraGVyamVlLCBELjwvYXV0aG9yPjxhdXRob3I+TmV3YnksIEwuIEsuPC9h
dXRob3I+PGF1dGhvcj5PJmFwb3M7R2FyYSwgUC4gVC48L2F1dGhvcj48YXV0aG9yPlNhYmF0aW5l
LCBNLiBTLjwvYXV0aG9yPjxhdXRob3I+U21pdGgsIFAuIEsuPC9hdXRob3I+PGF1dGhvcj5TbWl0
aCwgUy4gQy4sIEpyLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVzPjx0
aXRsZT4yMDE2IEFDQy9BSEEgZ3VpZGVsaW5lIGZvY3VzZWQgdXBkYXRlIG9uIGR1cmF0aW9uIG9m
IGR1YWwgYW50aXBsYXRlbGV0IHRoZXJhcHkgaW4gcGF0aWVudHMgd2l0aCBjb3JvbmFyeSBhcnRl
cnkgZGlzZWFzZTogYSByZXBvcnQgb2YgdGhlIEFtZXJpY2FuIENvbGxlZ2Ugb2YgQ2FyZGlvbG9n
eS9BbWVyaWNhbiBIZWFydCBBc3NvY2lhdGlvbiBUYXNrIEZvcmNlIG9uIENsaW5pY2FsIFByYWN0
aWNlIEd1aWRlbGluZXM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SiBBbSBDb2xsIENhcmRpb2w8
L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIEFtIENv
bGwgQ2FyZGlvbDwvZnVsbC10aXRsZT48YWJici0xPkouIEFtLiBDb2xsLiBDYXJkaW9sLjwvYWJi
ci0xPjwvcGVyaW9kaWNhbD48cGFnZXM+MTA4MuKAkzExNTwvcGFnZXM+PHZvbHVtZT42ODwvdm9s
dW1lPjxudW1iZXI+MTA8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QUNDL0FIQSBDbGluaWNh
bCBQcmFjdGljZSBHdWlkZWxpbmU8L2tleXdvcmQ+PGtleXdvcmQ+UDJZKDEyKSBpbmhpYml0b3I8
L2tleXdvcmQ+PGtleXdvcmQ+YWN1dGUgY29yb25hcnkgc3luZHJvbWU8L2tleXdvcmQ+PGtleXdv
cmQ+YXNwaXJpbjwva2V5d29yZD48a2V5d29yZD5jb3JvbmFyeSBhcnRlcnkgZGlzZWFzZTwva2V5
d29yZD48a2V5d29yZD5jb3JvbmFyeSBzdGVudHM8L2tleXdvcmQ+PGtleXdvcmQ+ZHVhbCBhbnRp
cGxhdGVsZXQgdGhlcmFweSAoREFQVCk8L2tleXdvcmQ+PGtleXdvcmQ+Zm9jdXNlZCB1cGRhdGU8
L2tleXdvcmQ+PGtleXdvcmQ+c3RhYmxlIGlzY2hlbWljIGhlYXJ0IGRpc2Vhc2U8L2tleXdvcmQ+
PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPlNlcCAw
NjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE1NTgtMzU5NyAoRWxlY3Ryb25pYykm
I3hEOzA3MzUtMTA5NyAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjcwMzY5MTg8L2Fj
Y2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPjxzdHlsZSBmYWNlPSJ1bmRlcmxp
bmUiIGZvbnQ9ImRlZmF1bHQiIHNpemU9IjEwMCUiPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5n
b3YvcHVibWVkLzI3MDM2OTE4PC9zdHlsZT48L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVs
ZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMTYvai5qYWNjLjIwMTYuMDMuNTEzPC9lbGVjdHJv
bmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=
ADDIN EN.CITE.DATA 6USAPatients with SIHDDAPT for a minimum of 1 month after BMS implantation DAPT for a minimum of 6 months in patients with stable CAD treated with DES implantation (3 months may be reasonable in patients with a high risk of bleeding or who develop significant overt bleeding)DAPT for more than 12 months for an MI within the previous 1–3 years may be reasonable, but only in patients at low bleeding riskDAPT for 12 months after CABG may be reasonable to improve vein graft patencyIn patients treated with DAPT, aspirin 81 mg per day (ranging from 75 mg to 100 mg per day) is recommended alongside clopidogrelDAPT is not beneficial in patients without a history of ACS, coronary stent implantation, or CABG ≤12 monthsCCS (2014)PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYW5jaW5pPC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYW5jaW5pPC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48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ADDIN EN.CITE.DATA 7CanadaPatients with SIHDAspirin (81 mg per day) or clopidogrel (75 mg per day) in case of aspirin intolerance DAPT should not be used in routine management of SIHD or beyond the time period required as a result of stenting aAn update to these guidelines was published in April 2018 (SIGN151)ACC, American College of Cardiology; AATS, American Association for Thoracic Surgery; ACCF, American College of Cardiology Foundation; ACP, American College of Physicians; AHA, American Heart Association; BMS, bare-metal stent; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS, Canadian Cardiology Society; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; ESC, European Society of Cardiology; HAS, National Authority for Health; MI, myocardial infarction; NICE, National Institute for Health and Care Excellence; PCNA, Preventive Cardiovascular Nurses Association; SCAI, Society for Cardiovascular Angiography and Interventions; SIGN, Scottish?Intercollegiate Guidelines Network; SIHD, stable ischemic heart disease; STS, Society of Thoracic SurgeonsSupplementary Table 3 Guideline recommendations on the use of antiplatelet therapy in patients with PADGuideline/Country Population Recommendations ESC (2017)EUSymptomatic carotid stenosisLong-term single antiplatelet therapy, aspirin (75–100 mg per day) or clopidogrel (75 mg per day) as an alternative in patients with aspirin intolerance DAPT with aspirin and clopidogrel is recommended for at least 1 month after CAS Symptomatic patients with LEAD Long-term single antiplatelet therapy, aspirin (75–100 mg per day) or clopidogrel (75 mg per day) in symptomatic patients, in all patients who have undergone revascularization, and after infra-inguinal bypass surgery In patients requiring antiplatelet therapy, clopidogrel may be preferred over aspirin Patients with PAD and CAD DAPT may be prolonged beyond 1 month when there is a prior history (<1 year) of ACS and/or percutaneous coronary intervention HAS (2016b) FrancePatients with LEAD Lifelong aspirin therapy (75–325 mg per day) or clopidogrel (75 mg per day) in case of aspirin intolerance AHA/ACC (2016) USAPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HZXJoYXJkLUhlcm1hbjwvQXV0aG9yPjxZZWFyPjIwMTc8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 EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HZXJoYXJkLUhlcm1hbjwvQXV0aG9yPjxZZWFyPjIwMTc8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 EN.CITE.DATA 8Patients with LEAD Aspirin alone (75–325 mg per day) or clopidogrel alone (75 mg per day) DAPT (aspirin and clopidogrel) may be reasonable to reduce the risk of limb-related events in patients with symptomatic PAD after lower extremity revascularizationCilostazol to improve symptoms and increase walking distance in patients with claudication CCS (2005) CanadaPatients with symptomatic PAD Lifelong aspirin therapy (75–325 mg per day) or clopidogrel (75 mg per day) in case of aspirin intolerance CCS (2011) CanadaPatients with symptomatic PAD Low-dose aspirin (75–162 mg per day) or clopidogrel (75 mg per day) providing the bleeding risk is low (Class IIb, Level B)Choice of drug may depend on patient preference and cost considerations Patients with symptomatic PAD with overt CAD or CeVD Antiplatelet therapy as indicated for CAD and/or CeVD (Class I, Level A) ACC, American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; CAD, coronary artery disease; CAS, carotid artery stenosis; CCS, Canadian Cardiology Society; CeVD, cerebrovascular disease; DAPT, dual antiplatelet therapy; ESC, European Society of Cardiology; HAS, National Authority for Health; LEAD, lower extremity artery disease; PAD, peripheral artery diseaseSUPPLEMENTARY FIGURE 1 PRISMA diagram of the searchReferences ADDIN EN.REFLIST 1.Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003.2.Haute Autorité de Santé. Artériopathie oblitérante des membres inférieurs [Obliterative arteriopathy of the lower limbs]. . Accessed 22 January 2019. 3.National Institutes of Health. Stable angina: management. . Accessed 22 January 2019. 4.Scottish Intercollegiate Guidelines Network. Management of stable angina: a national clinical guideline 96. . Accessed 22 January 2019. 5.Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354–e471.6.Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1082–1115.7.Mancini GB, Gosselin G, Chow B, et al. Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. Can J Cardiol. 2014;30:837–849.8.Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69:e71–e126. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- using coronary artery calcium to guide antihypertensive
- clinical acute coronary syndromes
- statin fibrate report focus on safety
- what is cardiac rehabilitation bcbsvt
- this application will build on the successes of the
- needs statement american medical seminars
- rajiv gandhi university of health sciences karnataka
- hindawi publishing corporation
- pharmacotherapy of coronary artery disease stable angina
Related searches
- publishing companies accepting submis
- list of book publishing companies
- publishing companies accepting submissions
- self publishing companies
- traditional book publishing companies
- nature publishing group journals
- best traditional publishing companies
- publishing companies for new writers
- list of traditional publishing companies
- publishing articles in journals
- best 10 self publishing companies
- book publishing submissions